I see your point. But consider that drug generations are generally not defined by the manufacturer, but by the broad community of researchers and clinicians finding step-changes in their effectiveness/side-effect tradeoffs.

So by definition, if they ever consider a "new generation" of GLP1-agonists, they will be better by definition.